Loading...
Loading...
SLDB| Name | Value |
|---|---|
| Revenues | 4.7M |
| Cost of Revenue | 0.6M |
| Gross Profit | 4.1M |
| Operating Expense | 21.7M |
| Operating I/L | -22.3M |
| Other Income/Expense | 1.9M |
| Interest Income | 1.7M |
| Pretax | -20.3M |
| Income Tax Expense | 4.6M |
| Net Income/Loss | -20.3M |
Solid Biosciences Inc. is a biotechnology company focused on developing therapies for Duchenne muscular dystrophy. Its lead product candidate, SGT-001, is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. The company also develops SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy. Solid Biosciences Inc. also works on platform technologies, including dual gene expression and novel capsids. The company generates revenue through the development and potential commercialization of gene therapies for Duchenne muscular dystrophy, including its collaboration and license agreement with Ultragenyx Pharmaceutical Inc.
